STOCK TITAN

Hims & Hers Health Inc Stock Price, News & Analysis

HIMS NYSE

Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.

Hims & Hers Health Inc (HIMS) delivers innovative telehealth solutions through its direct-to-consumer platform, connecting users with licensed professionals for personalized care, wellness products, and prescription services. This news hub provides investors and industry observers with essential updates about the company’s operational milestones and market developments.

Access real-time announcements including quarterly earnings reports, strategic partnerships, product expansions, and regulatory filings. Our curated collection ensures you stay informed about HIMS’ position in the competitive digital healthcare sector without needing to track multiple sources.

Key updates across these areas:

Financial Performance: Earnings calls and SEC filings
Service Innovations: New telehealth offerings and treatment categories
Strategic Growth: Partnerships and market expansion initiatives
Regulatory Compliance: FDA updates and healthcare policy impacts

Bookmark this page for streamlined access to verified HIMS developments. Combine these updates with our analysis tools on Stock Titan to monitor the company’s evolving role in reshaping accessible healthcare solutions.

Rhea-AI Summary

Hims & Hers Health reported a strong Q3 2022 with a revenue of $144.8 million, up 95% year-over-year. The company gained over 170,000 net new subscriptions, totaling 991,000 subscriptions, representing an 80% increase year-over-year. Hims & Hers raised its 2022 revenue guidance to $519-$522 million and expects Adjusted EBITDA of $(20) million to $(18) million. Despite a net loss of $(18.8) million, the company aims for Adjusted EBITDA profitability in Q4 2022, citing operational leverage and consumer adoption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.7%
Tags
-
Rhea-AI Summary

Hims & Hers Health, Inc. (NYSE: HIMS) will report its third quarter 2022 financial results after the market closes on November 7, 2022. A conference call to discuss the results will be held at 5:00 p.m. ET, accessible via U.S. dialing at (888) 510-2630 and internationally at (646) 960-0137, with conference ID 1704296. Hims & Hers is a consumer-first health platform offering treatments for various conditions, connecting patients with healthcare professionals for prescription fulfillment through a subscription model.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
-
Rhea-AI Summary

Hims & Hers Health, Inc. (NYSE: HIMS) has appointed Brian O’Shaughnessy as Chief Communications Officer and Josh Krueger as VP of Fulfillment Operations. O’Shaughnessy brings over two decades of experience from Google and Skype, where he led notable product communications. Krueger, formerly at Walmart and Amazon, has significant expertise in fulfillment operations. These hires aim to enhance Hims & Hers’ growth and improve customer experiences, following strong financial results with over $100 million in revenue and 100,000 new subscribers in Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
News
Rhea-AI Summary

Hims & Hers Health has launched its mobile apps on Android following a successful iOS rollout in Q1 2022. This expansion allows users to engage with the brand 3x more than before. The apps offer features such as subscription management, shipment tracking, and access to medical experts. They include innovative programs designed to improve consumer wellness. The company aims to enhance access to healthcare and wellness solutions, serving a broad range of health conditions through its platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
-
Rhea-AI Summary

Hims & Hers Health reported Q2 2022 revenue of $113.6 million, marking an 87% year-over-year increase. The company achieved over 100k net new subscriptions, totaling 817,000, an 80% increase from the previous year. Hims & Hers raised its full-year 2022 revenue guidance to $470 million to $485 million, with an adjusted EBITDA forecast of $(27) million to $(20) million. The company anticipates adjusted EBITDA profitability within the next four quarters, driven by operational efficiencies and strong platform demand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
Rhea-AI Summary

Hims & Hers Health, Inc. will announce its second quarter 2022 financial results on August 8, 2022, at 4:15 p.m. E.T.. A conference call will follow at 5:00 p.m. E.T. Participants can join by dialing +1 (888) 510-2630 for U.S. callers or +1 (646) 960-0137 for international callers, with the conference ID #1704296. The call will also be available via a live audio webcast. Hims & Hers offers a multi-specialty telehealth platform and serves a variety of health needs, with operations in the U.S. and the U.K.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
conferences earnings
-
Rhea-AI Summary

Hims & Hers Health, Inc. has launched a new line of supplements, Hers Wellness Essentials, specifically designed for women. The six products target various health concerns, including general health, mental wellness, gut health, digestive health, skin health, and libido. Available at CVS Pharmacy and other online platforms, these gluten-free, non-GMO, and vegetarian supplements utilize effective, naturally occurring ingredients. This expansion signifies Hims & Hers' commitment to offering personalized wellness options tailored to women's unique health needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none
-
Rhea-AI Summary

Hims & Hers reported Q1 2022 revenue of $101.3 million, a 94% increase year-over-year, surpassing the $100 million mark for the first time. The company also achieved a net loss of $(16.3) million, improved from $(51.4) million in Q1 2021. Member subscriptions grew by 101,000 to 710,000, an 82% increase. The company raised its full year 2022 revenue guidance to between $410 million and $425 million, while maintaining Adjusted EBITDA guidance of $(30 million) to $(20 million).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
Rhea-AI Summary

Hims & Hers Health, Inc. (NYSE: HIMS) will report its Q1 2022 financial results on May 9, 2022, at 4:15 p.m. E.T., followed by a conference call at 5:00 p.m. E.T. Participants can dial +1 (888) 510-2630 for U.S. access or +1 (646) 960-0137 for international access, using conference ID #1704296. A live audio webcast will be available at investors.forhims.com, with a replay accessible for 12 months.

Hims & Hers is a telehealth platform offering diverse healthcare services and can be accessed via a mobile app and retail locations across the U.S. and the U.K.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
conferences earnings

FAQ

What is the current stock price of Hims & Hers Health (HIMS)?

The current stock price of Hims & Hers Health (HIMS) is $44.57 as of August 22, 2025.

What is the market cap of Hims & Hers Health (HIMS)?

The market cap of Hims & Hers Health (HIMS) is approximately 9.8B.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Stock Data

9.80B
193.69M
10.63%
89.01%
28.61%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO